Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy

Journal of Clinical Investigation

Volumn 126, Issue 7, 2016, Pages 2519-2532

  Tomas, Nicola M ^a   Hoxha, Elion ^a   Reinicke, Anna T ^a   Fester, Lars ^a   Helmchen, Udo ^a   Gerth, Jens ^b   Bachmann, Friederike ^c   Budde, Klemens ^c   Koch Nolte, Friedrich ^a   Zahner, Gunther ^a   Rune, Gabriele ^a   Lambeau, Gerard ^d   Meyer Schwesinger, Catherine ^a   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Heinrich Braun Klinikum Zwickau   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RITUXIMAB; THROMBOSPONDIN 1; THROMBOSPONDIN TYPE 1 DOMAIN CONTAINING 7A; UNCLASSIFIED DRUG; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PHOSPHOLIPASE A2 RECEPTOR; PLA2R1 PROTEIN, HUMAN; THROMBOSPONDIN; THROMBOSPONDIN TYPE I DOMAIN CONTAINING 7A PROTEIN, HUMAN; THSD7A PROTEIN, MOUSE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CYTOSKELETON; DIALYSIS; DISEASE COURSE; EMBRYO; END STAGE RENAL DISEASE; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; NONHUMAN; PATHOGENICITY; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; STAINING; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULUS; IMMUNOLOGY; METABOLISM; MOUSE; PODOCYTE;

ALLOGRAFTS; ANIMALS; ANTIGENS, SURFACE; AUTOANTIBODIES; BIOPSY; CYTOSKELETON; GLOMERULONEPHRITIS, MEMBRANOUS; HEK293 CELLS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MIDDLE AGED; PODOCYTES; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2; RECURRENCE; THROMBOSPONDINS;

EID: 84978387836     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85265     Document Type: Article

References (34)

1. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med. 1959; 100 (4):660-664.
2. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol. 1996; 7 (12):2518-2526.
3. Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol. 1995; 6 (1):35-47.
4. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA. 1982; 79 (18):5557-5561.
5. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest. 1980; 66 (6):1339-1350.
6. Debiec H, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346 (26):2053-2060.
7. Beck LH Jr. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361 (1):11-21.
8. Tomas NM, et al. Thrombospondin type-1 domaincontaining 7A in idiopathic membranous nephropathy. N Engl J Med. 2014; 371 (24):2277-2287.
9. Vivarelli M, et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with antineutral endopeptidase antibodies. Kidney Int. 2015; 87 (3):602-609.
10. Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med. 2010; 363 (5):496-498.
11. Seitz-Polski B, et al. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. Nephrol Dial Transplant. 2014; 29 (12):2334-2342.
12. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. PLA2R antibody levels and clinical out-come in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS O ne. 2014; 9 (10):e110681.
13. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014; 25 (6):1357-1366.
14. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014; 9 (11):1883-1890.
15. Kanigicherla D, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013; 83 (5):940-948.
16. Meyer-Schwesinger C, Lambeau G, Stahl RA. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2015; 372 (11):1074-1075.
17. Gödel M, Grahammer F, Huber TB. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2015; 372 (11):1073.
18. Prunotto M, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010; 21 (3):507-519.
19. Kerjaschki D, et al. Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol. 1989; 143 (2):546-552.
20. Zamir E, Geiger B. Molecular complexity and dynamics of cell-matrix adhesions. J Cell Sci. 2001; 114 (pt 20):3583-3590.
21. Turner CE, Glenney JR, Burridge K. Paxillin: a new vinculin-binding protein present in focal adhesions. J Cell Biol. 1990; 111 (3):1059-1068.
22. Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol. 1992; 119 (4):893-903.
23. Beck LH Jr, Salant DJ. Membranous neph-ropathy: from models to man. J Clin Invest. 2014; 124 (6):2307-2314.
24. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol. 1989; 135 (1):185-194.
25. Spicer ST, et al. Induction of passive Heymann nephritis in complement component 6-deficient PVG rats. J Immunol. 2007; 179 (1):172-178.
26. Leenaerts PL, Hall BM, Van Damme BJ, Daha MR, Vanrenterghem YF. Active Heymann nephritis in complement component C6 deficient rats. Kidney Int. 1995; 47 (6):1604-1614.
27. Kerjaschki D, et al. Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis. J Clin Invest. 1997; 100 (9):2303-2309.
28. Buelli S, et al. Mitochondrial-dependent autoimmunity in membranous nephropathy of IgG4related disease. EBioMedicine. 2015; 2 (5):456-466.
29. Dähnrich C, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta. 2013; 421:213-218.
30. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011; 26 (8):2526-2532.
31. Möller S, et al. Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation. Purinergic Signal. 2007; 3 (4):359-366.
32. Somogyi P, Takagi H. A note on the use of picric acid-paraformaldehyde-glutaraldehyde fixative for correlated light and electron microscopic immunocytochemistry. Neuroscience. 1982; 7 (7):1779-1783.
33. Takemoto M, et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol. 2002; 161 (3):799-805.
34. Liu X, et al. Isolating glomeruli from mice: A practical approach for beginners. Exp Ther Med. 2013; 5 (5):1322-1326.